This ADC product is comprised of an anti-CD74 monoclonal antibody conjugated via a hindered disulfide linker to a Doxorubicin. The doxorubicin is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, doxorubicin binds to DNA, causes DNA damage.
ADC Target
- Alternative Names
- CD74; CD74 molecule, major histocompatibility complex, class II invariant chain; II; DHLAG; HLADG; Ia-GAMMA; HLA class II histocompatibility antigen gamma chain; p33; HLA-DR-gamma; MHC HLA-DR gamma chain; Ia-associated invariant chain; gamma chain of clas
- Target Entrez Gene ID
- 972
- Overview
- The protein encoded by this gene associates with class II major histocompatibility complex (MHC) and is an important chaperone that regulates antigen presentation for immune response. It also serves as cell surface receptor for the cytokine macrophage migration inhibitory factor (MIF) which, when bound to the encoded protein, initiates survival pathways and cell proliferation. This protein also interacts with amyloid precursor protein (APP) and suppresses the production of amyloid beta (Abeta). Multiple alternatively spliced transcript variants encoding different isoforms have been identified.
ADC Antibody
- Overview
- Humanized Anti-CD74 Antibody
ADC Linker
ADC payload drug
- Description
- Doxorubicin is the generic name for the trade name drug, Adriamycin?, as well as, Rubex?, which is a type of anti-cancer chemotherapy drug called an anthracycline. Doxorubicin works by blocking an enzyme called TopoisomeraseⅡthat cancer cells need to divide and grow.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products